Thomas Pfisterer

Mr. Pfisterer has served as a member of the Board of Directors of Imvax Inc. since 2019. In addition, he serves on the Boards of Directors of several other companies, including biotech companies; ADC Therapeutics (NYSE: ADCT) (Epalinges, CH), InSphero AG (Schlieren, CH) and Sermonix Pharmaceuticals Inc. (Columbus (OH), US).

Mr. Pfisterer holds a senior management role at WILD Group Management AG, heading the Direct Investments activities of the WILD Family Investment Office since 2015. Mr. Pfisterer joined the Family Office following the sale of WILD Flavors GmbH, one of the world’s leading suppliers of natural ingredients to the food and beverage industry, for which he served as Head of Strategic Development, directing the company’s global M&A activities since October 2011.